248 related articles for article (PubMed ID: 25597708)
41. Advances in the treatment of Kawasaki disease.
Dominguez SR; Anderson MS
Curr Opin Pediatr; 2013 Feb; 25(1):103-9. PubMed ID: 23283289
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
Kobayashi T; Kobayashi T; Morikawa A; Ikeda K; Seki M; Shimoyama S; Ishii Y; Suzuki T; Nakajima K; Sakamoto N; Arakawa H
J Pediatr; 2013 Aug; 163(2):521-6. PubMed ID: 23485027
[TBL] [Abstract][Full Text] [Related]
43. Kawasaki disease: part II. Complications and treatment.
Bayers S; Shulman ST; Paller AS
J Am Acad Dermatol; 2013 Oct; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
[TBL] [Abstract][Full Text] [Related]
44. Infections and Kawasaki disease: implications for coronary artery outcome.
Benseler SM; McCrindle BW; Silverman ED; Tyrrell PN; Wong J; Yeung RS
Pediatrics; 2005 Dec; 116(6):e760-6. PubMed ID: 16322132
[TBL] [Abstract][Full Text] [Related]
45. [Anti TNF-α (infliximab) treatment for intravenous immunoglobulin (IVIG) resistance patients with acute Kawasaki disease the effects of anticytokine therapy].
Saji T; Takatsuki S; Kobayashi T
Nihon Rinsho; 2014 Sep; 72(9):1641-9. PubMed ID: 25518416
[TBL] [Abstract][Full Text] [Related]
46. [Advance in diagnosis and treatment of intravenous immunogolobulin-resistant Kawasaki disease].
Zhang Q
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr; 11(4):318-21. PubMed ID: 19374823
[No Abstract] [Full Text] [Related]
47. Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis.
Xue LJ; Wu R; Du GL; Xu Y; Yuan KY; Feng ZC; Pan YL; Hu GY
Clin Rev Allergy Immunol; 2017 Jun; 52(3):389-400. PubMed ID: 27550227
[TBL] [Abstract][Full Text] [Related]
48. Treatment Options for Resistant Kawasaki Disease.
Phuong LK; Curtis N; Gowdie P; Akikusa J; Burgner D
Paediatr Drugs; 2018 Feb; 20(1):59-80. PubMed ID: 29101553
[TBL] [Abstract][Full Text] [Related]
49. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
50. Resistant Kawasaki disease treated with anti-CD20.
Sauvaget E; Bonello B; David M; Chabrol B; Dubus JC; Bosdure E
J Pediatr; 2012 May; 160(5):875-6. PubMed ID: 22341587
[TBL] [Abstract][Full Text] [Related]
51. Kawasaki disease in an 18-month-old boy.
Wróblewska-Kałuzewska M; Kucińska B; Werner B
Med Sci Monit; 2000; 6(6):1170-3. PubMed ID: 11208475
[TBL] [Abstract][Full Text] [Related]
52. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.
Newburger JW; Takahashi M; Beiser AS; Burns JC; Bastian J; Chung KJ; Colan SD; Duffy CE; Fulton DR; Glode MP
N Engl J Med; 1991 Jun; 324(23):1633-9. PubMed ID: 1709446
[TBL] [Abstract][Full Text] [Related]
53. Acute and late coronary outcomes in 1073 patients with Kawasaki disease with and without intravenous γ-immunoglobulin therapy.
Lin MT; Sun LC; Wu ET; Wang JK; Lue HC; Wu MH
Arch Dis Child; 2015 Jun; 100(6):542-7. PubMed ID: 25564534
[TBL] [Abstract][Full Text] [Related]
54. Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease.
Yanagimoto K; Nomura Y; Masuda K; Hirabayashi M; Morita Y; Yoshishige M; Ueno K; Eguchi T; Kawano Y
Int Arch Allergy Immunol; 2014; 164(2):83-8. PubMed ID: 24903098
[TBL] [Abstract][Full Text] [Related]
55. Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone.
Ogata S; Ogihara Y; Nomoto K; Akiyama K; Nakahata Y; Sato K; Minoura K; Kokubo K; Kobayashi H; Ishii M
Pediatr Res; 2009 Nov; 66(5):577-84. PubMed ID: 19680167
[TBL] [Abstract][Full Text] [Related]
56. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
Lee TJ; Kim KH; Chun JK; Kim DS
Yonsei Med J; 2008 Oct; 49(5):714-8. PubMed ID: 18972590
[TBL] [Abstract][Full Text] [Related]
57. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[TBL] [Abstract][Full Text] [Related]
58. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
Kuo HC; Wang CL; Liang CD; Yu HR; Chen HH; Wang L; Yang KD
J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
[TBL] [Abstract][Full Text] [Related]
59. Coronary artery fistula associated with Kawasaki disease.
Liang CD; Kuo HC; Yang KD; Wang CL; Ko SF
Am Heart J; 2009 Mar; 157(3):584-8. PubMed ID: 19249434
[TBL] [Abstract][Full Text] [Related]
60. The use of corticosteroid therapy in refractory Kawasaki patients.
Al-Mayouf SM
Clin Rheumatol; 2004 Feb; 23(1):11-3. PubMed ID: 14749974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
